Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Wimbledon Championships
Heatwaves
Stock Markets
Artificial Intelligence
Social Media
Donald Trump
Taxes
NHL
Republican Party
United Nations
Soccer
US Politics
Published • loading... • Updated

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002

Summary by Financial Post
GHENT, Belgium -- MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis.

1 Articles

All
Left
Center
Right
1
Financial PostFinancial Post
Lean Right

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002

GHENT, Belgium -- MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis.

·Canada
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Financial Post broke the news in Canada on Tuesday, April 16, 2024.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Ghent icon

Ghent

News
For You
SearchBlindspotLocal